These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38936947)

  • 41. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
    Matrana MR; Bathala T; Campbell MT; Duran C; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Tannir NM
    BJU Int; 2016 Aug; 118(2):264-71. PubMed ID: 26573089
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
    Rautiola J; Utriainen T; Peltola K; Joensuu H; Bono P
    Acta Oncol; 2014 Jan; 53(1):113-8. PubMed ID: 23721300
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictors of Long-Term Response With Pazopanib in Patients With Advanced Renal-Cell Carcinoma.
    Park J; Jiao X; Ghate S; Wilson T; Ahmad QI; Vogelzang NJ
    Clin Genitourin Cancer; 2018 Aug; 16(4):293-297. PubMed ID: 29653813
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma.
    McAlister RK; Aston J; Pollack M; Du L; Koyama T; Chism DD
    Oncologist; 2018 Jun; 23(6):686-692. PubMed ID: 29487220
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
    Grassi P; Verzoni E; Ratta R; Porcu L; Prisciandaro M; Mennitto A; Calareso G; de Braud F; Procopio G
    Drugs R D; 2017 Sep; 17(3):461-467. PubMed ID: 28801802
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-induced Hypertension in Metastatic Renal Cell Carcinoma.
    Penttilä P; Rautiola J; Poussa T; Peltola K; Bono P
    Clin Genitourin Cancer; 2017 Jun; 15(3):384-390.e3. PubMed ID: 28089721
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vanishing bile duct syndrome associated with pazopanib after progression on pembrolizumab.
    Zhong YY; McLean L; Buckle A; Siva S; Tran B
    Can J Urol; 2020 Aug; 27(4):10339-10341. PubMed ID: 32861263
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma.
    Bonate PL; Suttle AB
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):231-40. PubMed ID: 23715625
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Health care costs among renal cancer patients using pazopanib and sunitinib.
    Hansen RN; Hackshaw MD; Nagar SP; Arondekar B; Deen KC; Sullivan SD; Ramsey SD
    J Manag Care Spec Pharm; 2015 Jan; 21(1):37-44, 44a-d. PubMed ID: 25562771
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 51. External validation of nomograms for prediction of progression-free survival and liver toxicity in patients with advanced renal cell carcinoma treated with pazopanib.
    Okamura Y; Hinata N; Terakawa T; Furukawa J; Harada K; Nakano Y; Nakamura I; Inoue T; Ogawa T; Fujisawa M
    Int J Clin Oncol; 2019 Jun; 24(6):698-705. PubMed ID: 30798395
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
    Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Exploratory Investigation of Target Pazopanib Concentration Range for Patients With Renal Cell Carcinoma.
    Noda S; Yoshida T; Hira D; Murai R; Tomita K; Tsuru T; Kageyama S; Kawauchi A; Ikeda Y; Morita SY; Terada T
    Clin Genitourin Cancer; 2019 Apr; 17(2):e306-e313. PubMed ID: 30598361
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pazopanib for renal cell carcinoma leads to elevated mean arterial pressures in a murine model.
    Kempton A; Justice C; Guo A; Cefalu M; Makara M; Janssen P; Ho TH; Smith SA
    Clin Exp Hypertens; 2018; 40(6):524-533. PubMed ID: 29172746
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pazopanib-induced chylothorax in a patient with renal cell carcinoma.
    Koylu B; Tekin F; Aktas BY; Kilickap S; Koksal D
    Anticancer Drugs; 2022 Jan; 33(1):e555-e557. PubMed ID: 34387587
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma.
    Wood CG; Ferguson JE; Parker JS; Moore DT; Whisenant JG; Maygarden SJ; Wallen EM; Kim WY; Milowsky MI; Beckermann KE; Davis NB; Haake SM; Karam JA; Bortone DS; Vincent BG; Powles T; Rathmell WK
    JCI Insight; 2020 Nov; 5(22):. PubMed ID: 33208553
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term response to pazopanib in an elderly man with mRCC. A case report.
    D'Aniello C; Cavaliere C; Pisconti S; Facchini G
    Tumori; 2014; 100(6):e305-8. PubMed ID: 25688517
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.
    Bianconi M; Faloppi L; Loretelli C; Zizzi A; Giampieri R; Bittoni A; Andrikou K; Del Prete M; Burattini L; Montironi R; Scartozzi M; Cascinu S
    Oncotarget; 2016 Jun; 7(25):37599-37607. PubMed ID: 27175586
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Benefits of pazopanib over sunitinib for renal cell carcinoma.
    Granovetter M
    Lancet Oncol; 2016 Mar; 17(3):e93. PubMed ID: 26853821
    [No Abstract]   [Full Text] [Related]  

  • 60. Pazopanib for the treatment of renal cell carcinoma.
    Welsh SJ; Fife K
    Future Oncol; 2015; 11(8):1169-79. PubMed ID: 25832874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.